Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME)
05 janv. 2023 06h00 HE
|
Oculis
Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME) Oculis has completed enrollment for stage 1...
Oculis announces publication of positive Phase 2 data in Translational Vision Science & Technology (TVST) investigating topical anti-TNFα agent licaminlimab (OCS-02) in acute anterior uveitis
22 nov. 2022 06h00 HE
|
Oculis
Oculis announces publication of positive Phase 2 data in Translational Vision Science & Technology (TVST) investigating topical anti-TNFα agent licaminlimab (OCS-02) in acute anterior uveitis ...
Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology
17 oct. 2022 09h03 HE
|
Oculis
Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology Oculis is...
Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease
23 août 2022 06h03 HE
|
Oculis
Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease Positive Phase 2 data,...
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics
02 mars 2022 07h30 HE
|
Oculis
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics First-in-class peptidomimetic with distinct MoA activating...
Oculis appoints Dr. Bastian Dehmel as Chief Development Officer
08 févr. 2022 07h43 HE
|
Oculis
Oculis appoints Dr. Bastian Dehmel as Chief Development Officer Former Amgen Global Development Leader/OxThera CMO joins Oculis as Chief Development Officer to lead development planning and drive...
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)
05 janv. 2022 07h00 HE
|
Oculis
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China) Former Fresenius-Kabi China President to join Oculis in February 2022 to lead global operations and the...
Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02
06 mai 2021 10h00 HE
|
AGC Biologics
Seattle, May 06, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with Oculis to...